Market Closed -
Nasdaq
16:30:00 2024-06-14 EDT
5-day change
1st Jan Change
2.17
USD
-2.25%
0.00%
+0.46%
MyMD Pharmaceuticals, Inc. announced that it has received $14 million in funding from PharmaCyte Biotech, Inc.
On May 23, 2024, MyMD Pharmaceuticals, Inc. closed the transaction.
MyMD Pharmaceuticals, Inc. announced that it has received $14 million in funding from PharmaCyte Biotech, Inc.
05-22
CI
MyMD Pharmaceuticals, Inc. announced that it expects to receive $14 million in funding from PharmaCyte Biotech, Inc.
05-19
CI
PharmaCyte Biotech, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended January 31, 2024
03-18
CI
PharmaCyte Biotech, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended October 31, 2023
12-15
CI
Femasys Inc. announced that it has received $6.85 million in funding from PharmaCyte Biotech, Inc. and other investors
11-21
CI
Femasys Inc. announces tranche update
11-16
CI
Femasys Inc. announced that it expects to receive $6.85 million in funding from PharmaCyte Biotech, Inc.
11-13
CI
PharmaCyte Biotech, Inc. Provides Corporate Update on Cell-In-A-Box Technology
23-10-31
CI
Tranche Update on PharmaCyte Biotech, Inc.'s Equity Buyback Plan announced on February 2, 2023.
23-09-18
CI
PharmaCyte Biotech, Inc. Reports Earnings Results for the First Quarter Ended July 31, 2023
23-09-18
CI
Tranche Update on PharmaCyte Biotech, Inc.'s Equity Buyback Plan announced on February 2, 2023.
23-07-31
CI
PharmaCyte Biotech, Inc. Reports Earnings Results for the Full Year Ended April 30, 2023
23-07-31
CI
Tranche Update on PharmaCyte Biotech, Inc.'s Equity Buyback Plan announced on May 11, 2023.
23-06-15
CI
PharmaCyte Biotech, Inc.'s Equity Buyback announced on May 11, 2023, has closed with 8,085,879 shares, representing 48.15% for $26.46 million.
23-06-08
CI
PharmaCyte Biotech, Inc. announces an Equity Buyback for 7,750,000 shares, for $25.19 million.
23-05-11
CI
PharmaCyte Biotech, Inc authorizes a Buyback Plan.
23-05-10
CI
PharmaCyte Biotech, Inc. announced that it has received $35 million in funding
23-05-09
CI
PharmaCyte Biotech, Inc. announced that it expects to receive $35 million in funding
23-05-08
CI
Tranche Update on PharmaCyte Biotech, Inc.'s Equity Buyback Plan announced on February 2, 2023.
23-03-16
CI
Tranche Update on PharmaCyte Biotech, Inc.'s Equity Buyback Plan announced on June 2, 2022.
23-03-16
CI
PharmaCyte Biotech, Inc. announces an Equity Buyback for $10 million worth of its shares.
23-02-02
CI
PharmaCyte Biotech, Inc.'s Equity Buyback announced on June 2, 2022, has closed with 3,725,114 shares, representing 18.21% for $10 million.
23-01-30
CI
PharmaCyte Biotech, Inc. authorizes a Buyback Plan.
23-01-30
CI
Tranche Update on PharmaCyte Biotech, Inc.'s Equity Buyback Plan announced on June 2, 2022.
22-12-14
CI
PharmaCyte Biotech, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended October 31, 2022
22-12-14
CI
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
More charts
PharmaCyte Biotech, Inc. is a biotechnology company. It is focused on developing cellular therapies for cancer, diabetes, and malignant ascites based upon a cellulose-based live cell encapsulation technology known as Cell-in-a-Box. Its product candidate is referred to as CypCaps. The Cell-in-a-Box encapsulation technology potentially enables genetically engineered live human cells to be used to produce various biologically active molecules. It is advancing clinical research and development of new cellular-based therapies in oncology and diabetes. It is also focused on developing therapies for pancreatic and other solid cancerous tumors by using genetically engineered live human cells. Its product candidate for the treatment of diabetes consists of encapsulated genetically modified insulin-producing cells. It is also focused on the benefits of the Cell-in-a-Box technology to develop therapies for cancer that involve prodrugs based upon certain constituents of the Cannabis plant.
More about the company
1st Jan change
Capi.
+0.46% 18.34M +41.96% 630B -7.15% 350B +18.77% 328B +8.79% 298B +18.02% 246B +1.27% 225B +11.95% 218B +3.68% 160B -4.38% 156B
Other Pharmaceuticals
+951% of historical
More than 20 years
Our Experts
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1
PHARMACYTE BIOTECH, INC. 
